Form 4: Organon & Co. Executive VP Daniel Karp Reports Stock Option Grant and RSU Vesting

Executive VP of Corporate Development at Organon & Co., Daniel Karp, reports the acquisition and disposal of common stock and derivative securities due to stock option grants and restricted stock unit (RSU) vesting on March 31, 2025.

Summary

• On March 31, 2025, Daniel Karp, Executive VP of Corporate Development at Organon & Co., reported transactions involving Organon's common stock and derivative securities.
• These transactions include the acquisition of common stock through the exercise of stock options and the vesting of restricted stock units (RSUs).
• Karp acquired 14,184, 11,338, 4,861 and 4,294 shares of common stock through option exercise.
• He also disposed of 4,446, 3,554, 1,524 and 1,346 shares to cover tax obligations related to the vesting of RSUs at a price of $14.51 per share.
• Karp was granted 99,009 stock options exercisable in three equal installments starting March 31, 2026.
• He was also granted 20,147 RSUs that will vest in three equal installments starting March 31, 2026.
• Following these transactions, Karp directly owns 43,169.46 shares of Organon common stock, 99,009 stock options and 28,369 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine and reflect standard executive compensation practices. The vesting schedules suggest a long-term commitment from the executive.

Positives

• The grant of stock options and RSUs to a key executive aligns their interests with those of the shareholders.
• The vesting schedule of the options and RSUs incentivizes long-term performance.

Future Outlook

The reported transactions indicate continued equity-based compensation for key executives, aligning their interests with the company's long-term performance.

Industry Context

Equity-based compensation is a common practice in the pharmaceutical industry to attract and retain top talent and align their interests with shareholder value.

Comparison to Industry Standards

• Comparing Organon's executive compensation structure to peers like Pfizer, Merck, and Johnson & Johnson would provide a benchmark for assessing the competitiveness and appropriateness of the equity-based compensation.
• Reviewing proxy statements of these companies would reveal the typical mix of salary, bonus, stock options, and restricted stock units awarded to executives in similar roles.
• Benchmarking the vesting schedules and performance metrics associated with these equity grants would further refine the comparison.

Stakeholder Impact

• Shareholders may view the equity-based compensation positively as it aligns management's interests with long-term value creation.
• Employees may see the executive compensation as a sign of the company's commitment to rewarding performance.

Key Dates

Keywords

Organon & Co., Daniel Karp, Stock Options, RSU, Form 4, Executive Compensation, Beneficial Ownership, Insider Trading